Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal recessive disorder characterized mainly by symmetrical and selective atrophy of the proximal limb muscles. It derives from defects in the human CAPN3 gene, which encodes the skeletal muscle-specific member of the calpain family. This report represents a compilation of the mutations and variants identified so far in this gene. To date, 97 distinct pathogenic calpain 3 mutations have been identified (4 nonsense mutations, 32 deletions/insertions, 8 splice-site mutations, and 53 missense mutations), 56 of which have not been described previously, together with 12 polymorphisms and 5 nonclassified variants. The mutations are distributed along the entire length of the CAPN3 gene. Thus far, most mutations identified represent private variants, although particular mutations have been found more frequently. Knowledge of the mutation spectrum occurring in the CAPN3 gene may contribute significantly to structure/ function and pathogenesis studies. It may also help in the design of efficient mutation-screening strategies for calpainopathies.
Introduction
Limb-girdle muscular dystrophy type 2A (LGMD2A [ MIM 253600]) is an autosomal recessive disorder characterized by symmetrical and selective atrophy of the pelvic, scapular, and trunk muscles; elevated serum cre-atine kinase; and a necrotic regeneration pattern on muscular biopsies. Classically, calf hypertrophy is rare and always discrete, and there is no mental, cardiac, or facial disturbance. In the vast majority of cases, the symptoms arise in childhood, progress gradually, and, 10-20 years after onset, patients are frequently unable to walk and are confined to a wheelchair . A limb-girdle muscle involvement can also be recognized in a number of muscular disorders-in particular, in the other progressive muscular dystrophies that also have been regrouped under the term "LGMD2"; the latter comprise the four sarcoglycanopathies (LGMD2C-LGMD2F; (Roberds et al. 1994; Bö nnemann et al. 1995; Lim et al. 1995; Noguchi et al. 1995; Nigro et al. 1996) , which are characterized by a disruption of the sarcoglycan complex (Campbell 1995) , and three additional LGMD2 entities (LGMD2B, LGMD2G, and LGMD2H [Bashir et al. 1994; Moreira et al. 1997; Weiler et al. 1998 ]), which present no alterations in the sarcoglycan complex. The causative gene for LGMD2B recently has been identified as coding for dysferlin (Bashir et al. 1998; Liu et al. 1998) .
The gene responsible for LGMD2A had been localized, by linkage and linkage-disequilibrium analyses, to chromosome 15q15.1-15.3, within a 1-cM region almost entirely covered by a 1.6-Mb YAC (Beckmann et al. 1991; Fougerousse et al. 1994; Allamand et al. 1995) . Characterization of genes from this region led eventually to the identification of the LGMD2A gene that encodes calpain 3, a member of the calpain family . The latter regroups nonlysosomal calcium-dependent cysteine proteases, whose precise functional roles remain elusive.
The human calpain 3 gene (CAPN3) covers a genomic region of ∼40 kb . It is expressed predominantly in the skeletal muscle tissue, as a 3.5-kb transcript, driving the translation of a 94-kD protein containing a proteolytic domain, a Ca ϩϩ -activated domain, and two other domains with no known homology a For each mutation, two sequences are used-one corresponding to the normal allele (1) and the other corresponding to the mutated allele (2). (Sorimachi et al. 1989 ). In addition, CAPN3 has three unique sequences-NS, IS1, and IS2. Additional transcripts resulting from alternative splicing and alternative promoter use have been characterized (Ma et al. 1998a (Ma et al. , 1998b Herasse et al., in press; F. Fougerousse, personal communication) .
Since the discovery of the molecular defect in LGMD2A, we have collectively undertaken studies to determine the nature, number, and distribution of CAPN3 mutations and to assess potential genotype-phenotype correlations. To date, 97 distinct mutations have been identified, 56 of which have not been described previously.
Subjects and Methods

Description of Families and Preparation of Samples from Patients
This report summarizes studies, performed in five laboratories (Généthon [France], Hospital Ntra. Sra. Aranzazu [Spain] , Hospital Sant Pau [Spain] , the DNA diagnostic laboratory [Netherlands] , and University of Newcastle upon Tyne [United Kingdom), of families from diverse ethnic or geographic origins (including Brazil, Bulgaria, Canada, France, Greece, Israel, Italy, Japan, Lebanon, the Netherlands, Poland, Portugal, Russia, Spain, Switzerland, Turkey, United Kingdom, United States, and Vietnam). Families with LGMD that were from of the U.S. Amish community, from Réunion Island, and Basque country were distinguished from, respectively, families in the remaining United States, Metropolitan French (i.e., continental France), and Spanish families, since each of them represents a particular genetic isolate with a predominant founder effect. All patients presented in this report fulfill the clinical criteria of a classic LGMD phenotype-namely, autosomal recessive inheritance, progression of muscle weakness in a limb-girdle distribution (with sparing of facial muscles), and a clearly dystrophic muscle biopsy (Fardeau et al. 1996a (Fardeau et al. , 1996b . Calpain 3-deficient patients were also ascertained by the Newcastle group, by demonstration of both reduced 94-kD-band labeling and preserved sarcoglycans and dystrophin on western blots of skeletal-muscle biopsies (Anderson et al. 1998) . a Based on study of 1100 independent chromosomes; ND ϭ not determined.
Altogether, 180 families were selected on the basis of identification of variation in the CAPN3 gene. Several series of control chromosomes were examined, including those of the parents of patients, those of CEPH individuals, and/or those of control individuals from matched geographic origins. Genomic DNA was prepared from either peripheral-blood lymphocytes or cultures of lymphoblastoid cell lines.
Identification of DNA Sequence Variants
There was no uniform strategy for variant identification, since different protocols were used in each of the centers involved. These protocols included the following:
1. Illegitimate transcription analyses of cDNA-These were performed as in the study by , by use of total cellular RNA extracted from lymphoblastoid cell lines, followed by a final characterization by DNA sequencing.
2. Heteroduplex analysis-Ten microliters of the PCR product were denatured at 94˚C for 5 min and were allowed to renature at room temperature for у1 h. The product was electrophoresed on Hydrolink gel prepared according to the manufacturer's recommendations. For PCR products of ∼150 bp, the conditions of migration are an overnight (∼16 h) run at 400 V. After the gel was stained by ethidium bromide, the products are visualized under UV light. Identification of the variant sequences was performed by DNA sequencing.
3. SSCP-Five microliters of the PCR products were denatured at 95ЊC for 5 min and cooled on ice, with 10 ml of loading buffer (95% formamide and 0.1% bromophenol blue). The samples were separated on 0.4-mmthick 6% acrylamide 5% glycerol gels in 0.5 # . Gels were run at room temperature, Tris-borate EDTA at 8 W for 16 h. The samples were transferred to nylon filters and hybridized with the primers used in the PCR, according to the ECL protocol (Amersham), as described by Vignal et al. (1993) . Identification of the variant sequences was performed by DNA sequencing.
4. Direct sequencing-One hundred nanograms of DNA were amplified under buffer and cycle conditions described by . Each exon was amplified by specific primers, chosen in introns. The products of PCR were directly sequenced, with the same primers, by dye-dideoxy sequencing, after purification through either Microcon devices (Amicon) or polyacrylamide gel Biogel P-25 (Bio-Rad).
5. Allele-specific PCR-Oligonucleotides for mutations 551DA, G222R, IVS6Ϫ1GrA, R489W, R489Q, R572W, R572Q, S744G, R748Q, R769Q, 1872CrT, 2069DCA, and 2362AGrTCATCT were designed such that their 3 bases were at the point of the mutation (table  1) . One hundred nanograms of DNA were amplified by touchdown PCR in a 50-ml volume containing 1 mM Tris-HCl, pH 8.8, 50 mM KCl, 1.5 mM MgCl 2 , 0.1% Triton X-100, 200 mM of each dNTP, 100 ng of each primer, and 2 units of Taq polymerase (Perkin-Elmer). It was necessary to add various amounts of formamide, to increase the specificity of some PCRs. After 5-min denaturation at 96ЊC, thermocycling was performed as follows: 94ЊC for 40 s and then 30-s annealing steps starting 5ЊC higher than the annealing temperature and decreasing 1ЊC every two cycles until the annealing temperature was reached. These steps were followed by 20 cycles at 94ЊC for 40 s and 30 s at the annealing temperature. After PCR, the products were electrophoresed on a 2% horizontal agarose gel stained with ethidium bromide.
Haplotype Analysis
Short tandem repeats covering a region of 1 cM at the LGMD2A locus at 15q15.2 (markers D15S514, D15S779, D15S782, D15S780, and D15S778) were The number of independent events is given either inside or above the symbol of the mutation. The 24 exons are indicated by unblackened boxes (with the exon numbers below them). The four domains (I-IV) and the muscle-specific sequences (NS, IS1, and IS2) of calpain 3 also are shown. used to assign haplotypes, as described in a previous publication .
Results
Altogether, 114 variants have been detected in the CAPN3 gene (table 2) . Ninety-seven mutations were identified after screening of the CAPN3 gene in a total of 180 families from 22 different ethnic or geographic origins. Ninety-six mutations were characterized in our laboratories, and the additional one (IVS5ϩ1GrA) was previously reported as having occurred in a German family (Hä ffner et al. 1998 ). In most families, both mutations were identified, with the exception of 24 families for which only one allele each has been uncovered. Twelve polymorphisms were uncovered in the course of these studies (table 3) . Five additional variants (table 4), found only in patients, were not demonstrated to be causative mutations and therefore could not be classified as belonging to either of the two formerly described groups.
Mutations Identified
A summary of all the CAPN3 mutations is presented intable 2 and figure 1. The names of the mutations follow published guidelines (Antonarakis 1998) . The mutations include 65 single-base-pair substitutions-which resulted in a change of amino acid in 53 cases, in premature stop codons in 4 cases, and in splicing defects in 8 cases. Twenty-three (35%) of these 65 point mutations affect a CpG dinucleotide. An additional 32 mutations were small insertions and/or deletions. Therefore, ∼45% (44/97) of the CAPN3 mutations are likely to result in a truncated protein and, therefore, are likely to be inactivating. For the missense mutations, the following arguments are used to infer their pathogenic nature: (i) the fact that they were not encountered in control populations (in general, у100 independent chromosomes were examined) and (ii) the observation that all but one of these mutations involve changes of amino acids that are strictly conserved among the human, mouse, rat, bovine, and porcine CAPN3 sequences, if not among all the calpains (table 5) . Furthermore, some mutations were demonstrated to induce consequences with regard to three biochemical characteristics of CAPN3-namely, titin-binding ability, autolysis capacity, and fodrinolysis capacity (Ono et al. 1998) .
Interestingly, one of the splicing mutation (1872CrT) changes the third base of a codon to a synonymous codon yet leads to both the creation of a novel internal splice site and the subsequent loss of the end of the exon and, eventually, to a premature in-phase stop codon . Demonstration of the pathogenic nature of this sequence variant required the examination of the transcription product. The seven remaining splice mutations are located within 5 or 3 splice sites. IVS5ϩ1GrA was reported to induce skipping of exon 5 (Hä ffner et al. 1998) , and IVS6Ϫ1AGrAA leads to the use of a cryptic splice site upstream in the intron. The consequences, at the RNA level, of the other splice-site mutations were not ex- amined, because cells were not available from these patients. Nevertheless, present knowledge of splicing mechanisms could be used to infer putative consequences, in accordance with the exon-definition model (Robberson et al. 1990 ). IVS9Ϫ9ArG generates a new dinucleotide, AG, that could potentially be used as a splicing anchor (Smith et al. 1989 ); use of the latter would result in a frameshift mutation, by addition of 8 bases a Only haplotypes corresponding to recurrent mutations are presented. Markers are listed according to their linear map order. The disease locus is located between markers D15S779 and D15S782. In situations in which the haplotype could not be reconstructed, the two alleles have been given, separated by a virgule (/). For all markers except D15S780, the numbers represent allele size (in bp); in the case of marker D15S780, the numbers represent allele designations as given in the CEPH database.
in the mRNA. IVS17ϩ1GrT, IVS17Ϫ1GrT, and IVS20Ϫ1AGrGG may lead to either single-exon skipping or cryptic-splice-site utilization.
Most of the deletion/insertion mutations caused a frameshift, leading to a secondary premature stop codon. Four of the mutations (DFPIQFVW, DFWSAL, DSYEALKG, and DK254), however, were in-frame deletions that would theoretically result only in limited amino acid deletions. Two mutations were slightly more complex and resulted in the combination of small insertions and deletions. 2317AAACArT consists of a 5-bp deletion of nucleotides 2317-2321 of the coding region, coupled with a 1-bp insertion, and 2362AGrTCATCT consists of a 2-bp deletion coupled with a 6-bp insertion. The net result in both cases is a shift in the reading frame, followed by a premature stop codon.
The first major genomic deletion in the calpain 3 gene was identified in a Basque patient. Reverse transcription-PCR of the illegitimate transcription products showed that exons 5-7 were missing. Since no sequence alteration was identified in the splice sites of exons 4-8, a genomic deletion was suspected. Two PCR primers-one located in exon 4 and the other located in exon 8-that, in normal genomic DNA, were separated by ∼7 kb, led to the amplification of a fragment of ∼1.5 kb in DNA from this patient, whereas no amplification was obtained in DNA from control individuals. Sequencing of the corresponding PCR product enabled us to identify the mutation event as a 5,328-bp deletion spanning exons 5-7. The 5 breakpoint is in the right arm of the 3 r5 -oriented Alu-Jb repeat in intron 4, and the 3 breakpoint maps to the left arm of the Alu-Sg repeat in intron 7, which is oriented in the same direction. The deletion therefore seems to result from an unequal recombination event between two adjacent Alu elements.
Polymorphisms
To date, 12 polymorphisms have been characterized in the CAPN3 gene (table 3). They were excluded from being LGMD2A mutations, because of their occurrence in normal healthy populations and/or occurrence along the same chromosome that has a mutation. The range of frequencies of these polymorphisms varies between !0.01% and 12% (table 3) . None of these polymorphisms is in linkage disequilibrium with a particular mutation. Three of the variants are due to CrT transitions. Three polymorphisms map in noncoding regions. Seven 
NsiI BspHI a Enzymatic sites corresponding to enzymes that cut too frequently to be used in an analysis are not given.
b Present only on genomic DNA, not on cDNA.
Figure 2
Evolution curves for LGMD2A patients. Functional stages are graded as I-VII, according to the Gardner-Medwin and Walton (1974) scale. Only the curves for patients for whom two points of the disease evolution are known are represented, whereas the calculation of means and duration takes into account all available data. exonic polymorphisms do not lead to an alteration of the encoded amino acid, and the majority of them involve the third base of a codon. The last two polymorphisms, E107K and A236T, which are present, respectively, in exons 2 and 5, lead to an amino acid substitution. It should be noted, however, that the minor variants correspond to an amino acid that can also be found at the equivalent positions in other members of the calpain family: for E107, a lysine is present at the equivalent position in the human nCL4 protein, and, for A236, a threonine is present at the corresponding position in rat, mouse, and porcine calpain 3, as well as in the human, mouse, rat, and chicken calpain 1 proteins. This suggests that these changes may not have major deleterious effects on the protein's function(s).
Unclassified Variants
Also detected were five changes that could not be classified as either a polymorphism or a deleterious mutation, even though they were observed only in patients (table 4) . One intronic change, leading to a deletion of a C in intron 11 at position Ϫ34 of exon 12, was observed in a homozygous state in a Japanese patient who was homozygous for a chromosome 15 haplotype. Two additional changes are single-base substitutions involving the third base of a codon: a TGCrTGT transversion at position 984 in exon 7 (C984rT [C328C] ) and a CTGrCTA transversion at position 1263 in exon 10
Figure 3
Location of missense mutations and in-frame deletions along the CAPN3 protein (G1263rA [L421L]). C984rT (C328) was observed in three unrelated LGMD2 families of different geographic origins but not in 1100 control individuals. We are confident that two of these families are authentic LGMD2A families, since one mutant allele already has been characterized. No additional changes were identified in the corresponding patients' DNA, despite exhaustive screening. G1263rA (L421) was encountered only in a Swiss family in which the segregation is consistent with the chromosome 15 location of the disease locus.
All these changes may represent neutral polymorphisms; however, it is also possible that they represent authentic LGMD2A mutations that affect the structure of the transcript. Unfortunately, no biopsies or cell lines were available for the corresponding patients. Hence, we could not examine whether these changes have consequences at the RNA level. We can, however, attempt to predict their putative manifestations on the transcription products. IVS12Ϫ34DC may affect the branch site, since it is located at the corresponding consensus position. C984rT and G1263rA create potential splicing sites, with scores of 59% and 80%, respectively (Shapiro and Senapathy 1987) . The last two unclassified variants, H774D and A798E, lead to a change in the amino acid composition; but the presence, at the corresponding position, of the variant amino acid in other members of the calpain family is a strong argument in favor of their representing rare innocuous polymorphisms (table 5) .
Recurrent Mutations or Founder Effect
Twenty-nine mutations were each found in more than one family; however, it is necessary to include a correction for founder effect, since several mutations have been amplified in specific populations. This is particularly true for the Amish community, in which the R769Q mutation is encountered in a homozygous state in all 19 families with LGMD2A that were tested. A predominant mutation is also observed in two other populations with high consanguinity. IVS6Ϫ1GrA and 2362AGrTCATCT are present on 160% (25/39) and 76% (42/55) of the carrier chromosomes in families from Réunion Island and in the Basque isolate, respectively. Haplotype analyses by microsatellite markers that flank the LGMD2A locus confirmed that the mutations derived from the same ancestral mutational event Urtasun et al. 1998) . The same analysis allowed us also to infer a relationship between families, even in the absence of any known genealogical or geographic link. In particular, the 550DA mutation observed in patients from eight different countries was found, each time the information was available, to be associated with the same LGMD2A marker haplotype. This is also the case for (i) Y537X and A702V, which are found in Turkish and metropolitan French families; (ii) R769Q, which is present in both Amish and metropolitan French families; and (iii) 2362AGrTCATCT, which is present in 2 North American, 1 Brazilian, 3 Réunion Island, and 49 Spanish families. In other cases, haplotype data allowed us to rule out the possibility of a common founder effect and suggested, instead, that the mutations represent events that have occurred several times independently. Overall, if only the clearly independent events are considered, the number of recurrent mutations collapses to seven, representing 16 independent events (table 6); among these mutations, five correspond to CrT transitions involving CpG sites. Thus, altogether, 105 independent mutations were observed.
Distribution of CAPN3 Mutations
Mutations are relatively evenly distributed over all exons of the calpain 3 gene, with the exception of exons 9, 12, 14, 23, and 24, all of which are among the smallest exons and in which no mutations have been found so far ( fig. 1 ). These exons are to be contrasted with exon 21, which carries an excess of mutations ( ). When P ! .01 the nature of the mutations is considered, exons 5, 11, and 21 show an excess of missense mutations ( , P ! .05 .001, and .05, respectively), and, when allowance is made for the small numbers, exons 15, 17, and 22 may show an excess of deletions or insertions. Interestingly, a mutation cluster spanning a region of 11 amino acids in exon 11 accounts for 18% (11/61) of the independent missense events. This may be due to the elevated number of CpG sites at this location. No differences in the distribution of mutations were observed between the four calpain 3 domains.
Rapid Screening for Particular Mutations
In some cases, rapid testing for the presence of a particular mutation in a patient's DNA may be important, especially in the case of recurrent or population-specific mutations. Direct sequencing may be the method of choice, but alternatives allowing the analysis of a great number of individuals exist. Some CAPN3 mutations can be tested rapidly because they cause a change in a restriction-enzyme site (table 7) . Short deletions could be tested directly by electrophoresis of the corresponding PCR products. In addition, we have developed allelespecific PCR assays (table 1) for the mutations present in families from the Amish community, from Réunion Island, and from the Basque country. This has allowed us to test rapidly the presence of the corresponding mutations in new patients with these origins. We also have done this for the frequently observed mutation 550DA, which is always associated with the same haplotype, allowing to test candidate carriers presenting either this particular haplotype or a related haplotype.
Phenotypic Characteristics of Patients with LGMD2A
Clinical information was available for 163 of the patients presented here. For many of them, clinical characteristics have been reported elsewhere, and a typical formula has been defined, first in patients from Réunion Island (Fardeau et al. 1996b ). This formula is characterized mainly by a symmetrical, very selective atrophic involvement of limb-girdle and trunk muscles, with the gluteus maximus and thigh adductors being most affected (Fardeau et al. 1996a (Fardeau et al. , 1996b . The same pattern of muscle involvement was also reported for 3/4 of the examined metropolitan French patients, with occasionally minor variations around this pattern. The same holds for the majority of LGMD2A patients of Turkish or Basque origin Topaloglu et al. 1997; Beckmann and Fardeau 1998; Urtasun et al. 1998) . Overall, there was a marked heterogeneity of severity. The mean age at onset is 13.7 years (range 2-40 years old; fig. 2 ), and the mean age at loss of walking ability is 17.3 years (range 5-39 years; fig. 2 ). No sex difference was evident in either age at onset or evolution.
In an attempt to draw correlations between the clinical severity and the nature of gene mutations, evolution curves associating age at onset and functional stages were separated and compared according to the nature of the mutations (null/null, null/missense, and missense/ missense) ( fig. 3) . The age at onset in patients carrying two null mutations is quite homogeneous and occurs generally at age 15 years. In contrast, age at onset in patients who either had two missense mutations or were compound heterozygotes for one missense mutation and one null mutation is much more variable and can occur as early as age 2.5 years or as late as age 40 years. Furthermore, patients carrying two null mutations lost walking ability at age !40 years, whereas patients with either one missense and one null mutation or two missense mutations had broader variability in the evolution curves. These data further confirm and extend prior observations regarding the relative severity of null mutations versus missense mutations.
Discussion
In this report, we have presented all the mutations and polymorphisms identified so far in CAPN3, the gene involved in LGMD2A. A total of 114 variants have been identified in the calpain 3 gene: 97 mutations, 12 polymorphisms, and 5 variants that could not be classified as either mutation or polymorphism. Until one assesses the impact of the latter on mRNA processing and stability, it may be difficult to ascertain the neutrality or nonpathogenicity of these variants. The precedent demonstration of the pathogenic character of the 1872CrT mutation, which does not change the nature of the encoded amino acid , confirms that one needs to interpret with caution the apparently "neutral" mutations.
The 97 mutations reported thus far, 56 of which are newly described, include 4 nonsense, 32 deletion/insertion, 8 splice-site, and 53 missense mutations. If we consider the additional, unclassified IVS12Ϫ34DC, C495rT, and G1263rA variants as causative mutations, then the number of mutations characterized thus far would total 100. The mutations are distributed along the length of the CAPN3 gene, with a slight mutational "hot spot" in exon 21. If we consider missense mutations alone, exon 11 shows a notable excess of mutations. This exon constitutes a good primary target for screening of mild calpainopathies, in light of the degree of disease severity of carriers of either two missense mutations or a missense mutation associated with a null mutation.
Most mutations (68/97 [70%]) represent private variants, although particular mutations were found more frequently. Among these particular mutations, 11 (38%) are associated with a founder effect, 7 (24%) are really recurrent, and no information was obtained for the remaining mutations. CAPN3 mutations were identified in 181 families originating from 19 countries, further demonstrating the worldwide distribution of the disease. For 24 families, only one mutant allele was identified, despite the fact that all coding regions in these patients have been examined. These observations therefore suggest that mutations may occasionally lie in an essential noncoding regions, such as the promoter region or an intron. We also have described the first large genomic deletion of the calpain 3 gene, which is due to an unequal recombination between two intragenic Alu elements. The methodologies usually used for mutation screening are not oriented toward identification of such alterations. It would be interesting, given the relatively high Alu-sequences content of the calpain 3 region, to verify what fraction of the 23 unidentified mutations can be explained by such events. For this purpose, it may be useful to resort to use of additional procedures, such as Southern blot.
Diagnostic Applications
After the initial confirmation of CAPN3 as the LGMD2A gene, the primary clinical motivation for performing a systematic mutation analysis was to provide accurate and unambiguous LGMD2A diagnosis for patients with progressive muscular dystrophies. In particular, the identification of mutations in a family allowed the latter to be classified as belonging to the LGMD2A group. This is of importance in light of (i) the genetic heterogeneity of LGMD2 (which has at least eight causative genes, LGMD2A-LGMD2H) and (ii) the difficulty in clinically distinguishing one entity from another. Even if it is now possible, with the help of antisarcoglycans antibodies, to test for defects in the corresponding proteins and to distinguish sarcoglycanopathies from the other progressive muscular dystrophies, unambiguous diagnosis still rests on the identification of the underlying mutations. Hence, genetic and immunochemical analyses provide important means by which to refine and simplify diagnosis.
The wide spectrum of CAPN3 mutations, the relative large size of the CAPN3 gene, and, finally, the fact that most mutations seem to be private and relatively evenly distributed over most calpain 3 exons create significant practical problems for diagnosis of calpainopathies. Because of all these characteristics, no single mutationdetection method appears to be ideal, and the challenge of mutation identification remains important. The assessment of the calpain 3 protein in muscle biopsies, by either western blot or immunohistochemistry, may become an additional tool with which to investigate calpainopathies, although it should be remembered that the autoproteolytic nature of calpain 3 could render this diagnostic test difficult to interpret (Anderson et al. 1998; Beckmann and Fardeau 1998) . Nevertheless, the potential of this diagnostic strategy, which has been followed by the Newcastle team, is clearly demonstrated in the present study.
Since the realization of an objective molecular-genetic diagnosis still presents a formidable challenge, it could be helpful, whenever possible, before a direct mutation search is performed, to further classify the family-or, at least, to exclude particular loci-by linkage analysis.
To streamline the genetic analyses, we have developed a fluorescent-marker kit, using a set of markers bracketing the LGMD2A-LGMD2F disease loci (Richard et al., in press) . In an additional step, haplotype analyses can be used to infer a common ancestral origin and thus to point to a specific mutation(s). The geographic origins of the patients is another element that can direct the mutation screening.
We also have reported herein the polymorphisms identified in the study of our patient's cohort, since it is essential, in a diagnostic test, to distinguish between them and the morbid DNA-sequence anomalies and, thereby, to prevent erroneous diagnosis. This is of particular importance in the detection of mutations in exons 1 and 22 and in intron 22, which contain polymorphisms that can reach 10%-12% heterozygosity in the population examined. The inclusion of appropriate controls in the mutation analysis of this exon will help us to distinguish between these neutral polymorphisms and causative mutations.
LGMD2 Phenotype
The availability of molecular diagnosis has enabled precise symptomatology, by identification of clues allowing the recognition of specific clinical features of calpainopathies, compared with other progressive muscular dystrophies caused by defects in structural proteins. Molecular classification of patients as belonging within the different LGMD2 forms helps us to validate the specific topography and characteristics of muscle involvement (for a precise description of LGMD2A patients, see (Fardeau et al. 1996a (Fardeau et al. , 1996b Dinçer et al. 1997; Topaloglu et al. 1997; Beckmann and Fardeau 1998; Urtasun et al. 1998) . To sum up, the typical formula with regard to calpain 3-deficient patients includes, in the early stage of the disease, a predominant wasting of muscles from the posterior compartments of the limbs, clearly visible by both clinical examination and computed-tomography (CT) scan, whereas in sarcoglycanopathies there is a marked quadriceps femoris involvement (Eymard et al. 1997 ). The differences, in the distribution of muscle wasting, between the different forms renders CT-scan analysis an important element in a clinical diagnosis. An additional sign that may help us to distinguish calpainopathies from sarcoglycanopathies is the fact that, in the former, calf hypertrophy is less frequent, whereas macroglossia is never seen.
Both the characterization of mutations and the study of phenotype/genotype correlations should allow us to elucidate the molecular basis for the expression of disparate phenotypes among calpain 3-deficient patients. No evident correlations between the mutations and the clinical manifestations of LGMD2A has been established, either between the families or even within the families, although, in general, null mutations result in clinical consequences that are more severe than those that result from missense mutations. Furthermore, the study of this large cohort of calpain 3-deficient patients has failed to show that the patient's gender has any influence on either age at onset or disease evolution.
Locus-Specific Database
Given both the widespread geographic distribution of this disease and the growing number of reported cases, it seems important, in order to help investigators and clinicians in their diagnostic process, to maintain and update a CAPN3-mutation database. With this goal in mind, we are in the process of constructing a locusspecific database Website in accordance with HUGO guidelines for content and structure of mutations databases, and we encourage others to join us and to participate in a collective effort to regroup all CAPN3 mutations in a publicly available database. Meanwhile, some of these data are already accessible in the Leiden Muscular Dystrophy pages.
